| Year |
Citation |
Score |
| 2022 |
Shah PA, Sambandam V, Fernandez AM, Zhao H, Mazumdar T, Shen L, Wang Q, Ahmed KM, Ghosh S, Frederick MJ, Wang J, Johnson FM. Sustained Aurora kinase B expression confers resistance to PI3K inhibition in head and neck squamous carcinoma. Cancer Research. PMID 36169922 DOI: 10.1158/0008-5472.CAN-22-1175 |
0.334 |
|
| 2022 |
Johnson FM, Janku F, Gouda MA, Tran HT, Kawedia JD, Schmitz D, Streefkerk H, Lee JJ, Andersen CR, Deng D, Rawal S, Shah PA, El-Naggar AK, Johnson JM, Frederick MJ. Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function NOTCH1-Mutant Head and Neck Cancer. The Oncologist. PMID 36124629 DOI: 10.1093/oncolo/oyac185 |
0.334 |
|
| 2022 |
Callahan SC, Kochat V, Liu Z, Raman AT, Divenko M, Schulz J, Terranova CJ, Ghosh AK, Tang M, Johnson FM, Wang J, Skinner HD, Pickering CR, Myers JN, Rai K. High enhancer activity is an epigenetic feature of HPV negative atypical head and neck squamous cell carcinoma. Frontiers in Cell and Developmental Biology. 10: 936168. PMID 35927986 DOI: 10.3389/fcell.2022.936168 |
0.305 |
|
| 2021 |
Gudikote JP, Cascone T, Poteete A, Sitthideatphaiboon P, Wu Q, Morikawa N, Zhang F, Peng S, Tong P, Li L, Shen L, Nilsson M, Jones P, Sulman EP, Wang J, ... ... Johnson FM, et al. Inhibition of nonsense-mediated decay rescues p53β/γ isoform expression and activates the p53 pathway in MDM2-overexpressing and select p53-mutant cancers. The Journal of Biological Chemistry. 101163. PMID 34481841 DOI: 10.1016/j.jbc.2021.101163 |
0.304 |
|
| 2021 |
Stewart CA, Gay CM, Ramkumar K, Cargill KR, Cardnell RJ, Nilsson MB, Heeke S, Park EM, Kundu ST, Diao L, Wang Q, Shen L, Xi Y, Zhang B, Della Corte CM, ... ... Johnson FM, et al. Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 34274504 DOI: 10.1016/j.jtho.2021.07.002 |
0.31 |
|
| 2020 |
Shah PA, Huang C, Li Q, Kazi SA, Byers LA, Wang J, Johnson FM, Frederick MJ. NOTCH1 Signaling in Head and Neck Squamous Cell Carcinoma. Cells. 9. PMID 33322834 DOI: 10.3390/cells9122677 |
0.334 |
|
| 2020 |
Kamal M, Mohamed ASR, Fuller CD, Sturgis EM, Johnson FM, Morrison WH, Gunn GB, Hutcheson KA, Phan J, Volpe S, Ng SP, Phan J, Cardenas C, Ferrarotto R, Frank SJ, et al. Patterns of Failure After Intensity Modulated Radiation Therapy in Head and Neck Squamous Cell Carcinoma of Unknown Primary: Implication of Elective Nodal and Mucosal Dose Coverage. Advances in Radiation Oncology. 5: 929-935. PMID 33083655 DOI: 10.1016/J.Adro.2020.04.025 |
0.337 |
|
| 2020 |
Ferrarotto R, Bell D, Rubin ML, Hutcheson KA, Johnson JM, Goepfert RP, Phan J, Elamin YY, Torman Karagiannis DT, Warneke CL, Hessel AC, Garden AS, Myers JN, Johnson FM, Lee JJ, et al. Impact of neoadjuvant durvalumab with or without tremelimumab on CD8+ tumor lymphocyte density, safety, and efficacy in patients with oropharynx cancer: CIAO trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32269052 DOI: 10.1158/1078-0432.Ccr-19-3977 |
0.361 |
|
| 2020 |
Ng SP, Bahig H, Jethanandani A, Pollard C, Berends J, Sturgis EM, Johnson FM, Elgohari B, Elhalawani H, Rosenthal DI, Skinner HD, Gunn GB, Phan J, Frank SJ, Mohamed ASR, et al. Lymphopenia during radiotherapy in patients with oropharyngeal cancer. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 145: 95-100. PMID 31931292 DOI: 10.1016/J.Radonc.2019.12.023 |
0.422 |
|
| 2020 |
Johnson FM, Janku F, Lee JJ, Schmitz D, Streefkerk H, Frederick M. Single-arm study of bimiralisib in head and neck squamous cell carcinoma (HNSCC) patients (pts) harboring NOTCH1 loss of function (LOF) mutations. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.Tps6590 |
0.362 |
|
| 2020 |
Gunn GB, Ferrarotto R, Johnson FM, Bell D, Cardoso R, Johnson JM, Rubin ML, Yuan Y, Frank SJ, Fuller CD, Rosenthal DI, Kupferman ME, Goepfert R, Hessel AC, Hutcheson KA, et al. Prospective, longitudinal digital activity monitoring before and after treatment of low-risk oropharyngeal squamous cell carcinoma: A feasibility study. Journal of Clinical Oncology. 38: 6578-6578. DOI: 10.1200/Jco.2020.38.15_Suppl.6578 |
0.329 |
|
| 2020 |
Gleber-Netto FO, Gao M, Shen L, Wang J, Myers JN, Johnson FM, Pickering CR. Abstract B14: Variations in the proteasome activity are associated with human papilloma virus (HPV) gene expression and patient survival in HPV+ oropharyngeal tumors Clinical Cancer Research. 26. DOI: 10.1158/1557-3265.Aacrahns19-B14 |
0.341 |
|
| 2020 |
Sambandam V, Mazumdar T, Shen L, Zhao H, Peng S, Wang J, Johnson FM. Aurora kinases mediate resistance to PI3K inhibition in head and neck squamous cell carcinoma International Journal of Radiation Oncology Biology Physics. 106: 1184. DOI: 10.1016/J.Ijrobp.2019.11.117 |
0.405 |
|
| 2020 |
Barbon CE, Yao CM, Warneke CL, Elgohari B, Goepfert RP, Hessel AC, Kupferman ME, Lai S, Fuller CD, Gunn GB, Garden AS, Chronowski GM, Johnson FM, Lewin JS, Gross ND, et al. Dysphagia After Primary Tors vs Non-surgical Therapies for Low-to-Intermediate Risk Tonsil Cancer: A Prospective Registry Analysis International Journal of Radiation Oncology Biology Physics. 106: 1204. DOI: 10.1016/J.Ijrobp.2019.11.059 |
0.331 |
|
| 2019 |
Singh R, Peng S, Viswanath P, Sambandam V, Shen L, Rao X, Fang B, Wang J, Johnson FM. Non-canonical cMet regulation by vimentin mediates Plk1 inhibitor-induced apoptosis. Embo Molecular Medicine. PMID 31040125 DOI: 10.15252/Emmm.201809960 |
0.474 |
|
| 2019 |
Bloom BC, Augustyn A, Pezzi TA, Menon H, Mayo LL, Shah SJ, Schwartz DL, Chmura SJ, Johnson FM, Welsh JW, Chun SG. Rescue of Immunotherapy-Refractory Metastatic Merkel Cell Carcinoma With Conventionally Fractionated Radiotherapy and Concurrent Pembrolizumab. Frontiers in Oncology. 9: 223. PMID 31024834 DOI: 10.3389/Fonc.2019.00223 |
0.333 |
|
| 2019 |
Sambandam V, Frederick MJ, Shen L, Tong P, Rao X, Peng S, Singh R, Mazumdar T, Huang C, Li Q, Pickering CR, Myers JN, Wang J, Johnson FM. PDK1 mediates NOTCH1-mutated head and neck squamous carcinoma vulnerability to therapeutic PI3K/mTOR inhibition. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30770351 DOI: 10.1158/1078-0432.Ccr-18-3276 |
0.422 |
|
| 2019 |
Gleber-Netto FO, Rao X, Guo T, Xi Y, Gao M, Shen L, Erikson K, Kalu NN, Ren S, Xu G, Fisch KM, Akagi K, Seiwert T, Gillison M, Frederick MJ, ... Johnson FM, et al. Variations in HPV function are associated with survival in squamous cell carcinoma. Jci Insight. 4. PMID 30626753 DOI: 10.1172/Jci.Insight.124762 |
0.335 |
|
| 2019 |
Le X, Pickering CR, Rubin ML, Netto F, Kies MS, Johnson FM, Lu C, Blumenschein GR, Bell D, Ginsberg LE, Wilson KF, Lewis J, Feng L, Wang J, Lee JJ, et al. Induction chemotherapy with and without erlotinib in patients with oral cavity squamous cell carcinomas (OCSCCs) amenable for surgical resection. Journal of Clinical Oncology. 37: 6067-6067. DOI: 10.1200/Jco.2019.37.15_Suppl.6067 |
0.358 |
|
| 2019 |
Ferrarotto R, Bell D, Rubin ML, Lee JJ, Johnson JM, Goepfert R, Phan J, Elamin Y, Myers J, Hessel AC, Johnson FM, Gillison ML, Sikora AG, Glisson BS, Gross ND. Checkpoint inhibitors assessment in oropharynx cancer (CIAO): Safety and interim results. Journal of Clinical Oncology. 37: 6008-6008. DOI: 10.1200/Jco.2019.37.15_Suppl.6008 |
0.332 |
|
| 2019 |
Gleber-Netto FO, Gao M, Rao X, Vellano CP, Marszalek JR, Wang J, Johnson FM, Pickering CR. Abstract 4942: Variations in HPV function are associated with patient outcome and identify new candidate therapeutic approaches Cancer Research. 79: 4942-4942. DOI: 10.1158/1538-7445.Am2019-4942 |
0.346 |
|
| 2019 |
Sambandam V, Shen L, Peng S, Mazumdar T, Pickering C, Myers J, Wang J, Frederick M, Johnson F. Abstract 3913: PDK1 drives susceptibility ofNOTCH1mutant head and neck squamous carcinoma to PI3K/mTOR pathway inhibition Cancer Research. 79: 3913-3913. DOI: 10.1158/1538-7445.Am2019-3913 |
0.444 |
|
| 2019 |
Janku F, Johnson FM, Opyrchal M, Dowlati A, Hierro C, Forester M, Blagden SP, Wicki A, Schmitz D, Adjei AA. Abstract B109: Oral dual PI3K/mTOR inhibitor bimiralisib demonstrates tolerability and a signal of activity in head and neck squamous cell cancer with NOTCH1 loss-of-function mutation Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-B109 |
0.432 |
|
| 2019 |
Ng SP, Bahig H, Pollard C, Sturgis E, Johnson F, Elgohari B, Reddy J, Gunn GB, Phan J, Rosenthal D, Morrison W, Frank S, Fuller C, Garden A. Prognostic significance of pre-treatment neutrophil-to-lymphocyte ratio in patients with oropharyngeal cancer treated with radiotherapy International Journal of Radiation Oncology Biology Physics. 105. DOI: 10.1016/J.Ijrobp.2019.06.1541 |
0.328 |
|
| 2018 |
Haddad RI, Massarelli E, Lee JJ, Lin HY, Hutcheson K, Lewis J, Garden AS, Blumenschein GR, William WN, Pharaon RR, Tishler RB, Glisson BS, Pickering C, Gold KA, Johnson FM, et al. Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 30596812 DOI: 10.1093/Annonc/Mdy549 |
0.383 |
|
| 2018 |
Massarelli E, William W, Johnson F, Kies M, Ferrarotto R, Guo M, Feng L, Lee JJ, Tran H, Kim YU, Haymaker C, Bernatchez C, Curran M, Zecchini Barrese T, Rodriguez Canales J, et al. Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial. Jama Oncology. PMID 30267032 DOI: 10.1001/Jamaoncol.2018.4051 |
0.34 |
|
| 2018 |
Gay CM, Tong P, Cardnell RJ, Sen T, Su X, Ma J, Bara RO, Johnson FM, Wakefield C, Heymach JV, Wang J, Byers LA. Differential Sensitivity Analysis for Resistant Malignancies (DISARM) identifies common candidate therapies across platinum-resistant cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30257981 DOI: 10.1158/1078-0432.Ccr-18-1129 |
0.313 |
|
| 2018 |
Viswanath P, Peng S, Singh R, Kingsley C, Balter PA, Johnson FM. A Novel Method for Quantifying Total Thoracic Tumor Burden in Mice. Neoplasia (New York, N.Y.). 20: 975-984. PMID 30157470 DOI: 10.1016/J.Neo.2018.08.003 |
0.365 |
|
| 2018 |
Rodon J, Pérez-Fidalgo A, Krop IE, Burris H, Guerrero-Zotano A, Britten CD, Becerra C, Schellens J, Richards DA, Schuler M, Abu-Khalaf M, Johnson FM, Ranson M, Edenfield J, Silva AP, et al. Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer. Cancer Chemotherapy and Pharmacology. PMID 29882016 DOI: 10.1007/S00280-018-3610-Z |
0.388 |
|
| 2018 |
Kalu NN, Mazumdar T, Peng S, Tong P, Shen L, Wang J, Banerjee U, Myers JN, Pickering CR, Brunell D, Stephan CC, Johnson FM. Comprehensive pharmacogenomic profiling of human papillomavirus-positive and -negative squamous cell carcinoma identifies sensitivity to aurora kinase inhibition in KMT2D mutants. Cancer Letters. PMID 29807113 DOI: 10.1016/J.Canlet.2018.05.029 |
0.483 |
|
| 2018 |
Gold KA, Kies MS, William WN, Johnson FM, Lee JJ, Glisson BS. Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial. Cancer. PMID 29579331 DOI: 10.1002/Cncr.31346 |
0.448 |
|
| 2018 |
Lee WC, Diao L, Wang J, Zhang J, Roarty EB, Varghese S, Chow CW, Fujimoto J, Behrens C, Cascone T, Peng W, Kalhor N, Moran CA, Weissferdt A, Johnson FM, et al. Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 29410488 DOI: 10.1038/s41379-018-0029-3 |
0.369 |
|
| 2018 |
Kamal M, Mohamed ASR, Fuller CD, Sturgis EM, Johnson FM, Morrison WH, Gunn GB, Hutcheson KA, Phan J, Volpe S, Ng SP, Ferrarotto R, Frank SJ, Skinner HD, Rosenthal DI, et al. Outcomes of patients diagnosed with carcinoma metastatic to the neck from an unknown primary source and treated with intensity-modulated radiation therapy. Cancer. PMID 29338089 DOI: 10.1002/Cncr.31235 |
0.324 |
|
| 2018 |
Mazumdar T, Kalu NN, Peng S, Tong P, Shen L, Wang J, Myers JN, Pickering CR, Brunell D, Stephan CC, Johnson FM. Abstract 4646: Pharmacogenomic screen identifies KMT2D mutations as a biomarker of sensitivity to Aurora kinase inhibition in head and neck and cervical squamous cell carcinoma Cancer Research. 78: 4646-4646. DOI: 10.1158/1538-7445.Am2018-4646 |
0.494 |
|
| 2018 |
Sambandam V, Shen L, Tong P, Peng S, Mazumdar T, Singh R, Pickering CR, Myers JN, Wang J, Frederick M, Johnson FM. Abstract 2977: PI3K/mTOR pathway inhibition induces Aurora B mediated cell death in NOTCH1 mutant head and neck squamous (HNSCC) cells Cancer Research. 78: 2977-2977. DOI: 10.1158/1538-7445.Am2018-2977 |
0.47 |
|
| 2018 |
Ng S, Bahig H, Jethanandani A, Pollard C, Berends J, Sturgis E, Johnson F, Elgohari B, Elhalawani H, Mohamed A, Rosenthal D, Skinner H, Gunn G, Phan J, Frank S, et al. Lymphopenia During Radiation Therapy In Patients with Oropharyngeal Cancer: Does It Affect Survival Outcomes? International Journal of Radiation Oncology*Biology*Physics. 102: e309. DOI: 10.1016/J.Ijrobp.2018.07.967 |
0.342 |
|
| 2017 |
Gadhikar MA, Zhang J, Shen L, Rao X, Wang J, Zhao M, Kalu NN, Johnson FM, Byers LA, Heymach J, Hittelman WN, Udayakumar D, Pandita RK, Pandita TK, Pickering CR, et al. CDKN2A/p16 deletion in head and neck cancer cells is associated with Cdk2 activation, replication stress, and vulnerability to Chk1 inhibition. Cancer Research. PMID 29229598 DOI: 10.1158/0008-5472.Can-17-2802 |
0.42 |
|
| 2017 |
Kalu NN, Mazumdar T, Peng S, Shen L, Sambandam V, Rao X, Xi Y, Li L, Qi Y, Gleber-Netto FO, Patel A, Wang J, Frederick MJ, Myers JN, Pickering CR, ... Johnson FM, et al. Genomic characterization of human papillomavirus-positive and -negative human squamous cell cancer cell lines. Oncotarget. 8: 86369-86383. PMID 29156801 DOI: 10.18632/Oncotarget.21174 |
0.371 |
|
| 2017 |
Cardnell RJ, Li L, Sen T, Bara R, Tong P, Fujimoto J, Ireland AS, Guthrie MR, Bheddah S, Banerjee U, Kalu NN, Fan YH, Dylla SJ, Johnson FM, Wistuba II, et al. Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies. Oncotarget. 8: 73419-73432. PMID 29088717 DOI: 10.18632/Oncotarget.20621 |
0.469 |
|
| 2017 |
Kato S, Jardim DL, Johnson FM, Subbiah V, Piha-Paul S, Tsimberidou AM, Falchook GS, Karp D, Zinner R, Wheler J, Janku F, Fu S, Lim J, Bean S, Nguyen L, et al. Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. Investigational New Drugs. PMID 29047029 DOI: 10.1007/S10637-017-0513-5 |
0.394 |
|
| 2017 |
Quinlan-Davidson SR, Mohamed ASR, Myers JN, Gunn GB, Johnson FM, Skinner H, Beadle BM, Gillenwater AM, Phan J, Frank SJ, William WN, Wong AJ, Lai SY, Fuller CD, Morrison WH, et al. Outcomes of oral cavity cancer patients treated with surgery followed by postoperative intensity modulated radiation therapy. Oral Oncology. 72: 90-97. PMID 28797467 DOI: 10.1016/J.Oraloncology.2017.07.002 |
0.344 |
|
| 2017 |
Tanaka N, Patel AA, Tang L, Silver NL, Lindemann A, Takahashi H, Jaksik R, Rao X, Kalu NN, Chen TC, Wang J, Frederick MJ, Johnson FM, Gleber-Netto F, Fu S, et al. Replication stress leading to apoptosis within the S-phase contributes to synergism between vorinostat and AZD1775 in HNSCC harboring high risk TP53 mutation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28790110 DOI: 10.1158/1078-0432.Ccr-17-0947 |
0.479 |
|
| 2017 |
Kawakami M, Mustachio LM, Rodriguez-Canales J, Mino B, Roszik J, Tong P, Wang J, Lee JJ, Myung JH, Heymach JV, Johnson FM, Hong S, Zheng L, Hu S, Villalobos PA, et al. Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer. Journal of the National Cancer Institute. 109. PMID 28376145 DOI: 10.1093/Jnci/Djw297 |
0.45 |
|
| 2017 |
Bauman JE, Duvvuri U, Gooding WE, Rath TJ, Gross ND, Song J, Jimeno A, Yarbrough WG, Johnson FM, Wang L, Chiosea S, Sen M, Kass J, Johnson JT, Ferris RL, et al. Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer. Jci Insight. 2: e90449. PMID 28352657 DOI: 10.1172/Jci.Insight.90449 |
0.505 |
|
| 2017 |
Zhang M, Singh R, Peng S, Mazumdar T, Sambandam V, Shen L, Tong P, Li L, Kalu N, Pickering CR, Frederick M, Myers JN, Wang J, Johnson FM. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors. Cancer Letters. PMID 28126323 DOI: 10.1016/J.Canlet.2017.01.024 |
0.481 |
|
| 2017 |
Kalu NN, Johnson FM. Do CDK4/6 inhibitors have potential as targeted therapeutics for squamous cell cancers? Expert Opinion On Investigational Drugs. 1-11. PMID 28042706 DOI: 10.1080/13543784.2017.1274731 |
0.477 |
|
| 2017 |
William WN, Feng L, Kies MS, Ahmed S, Blumenschein GR, Glisson BS, Massarelli E, Johnson FM, Lu C, Papadimitrakopoulou V, Gold KA, Theriault RL, Heymach J, Kim ES. Randomized, double-blind, placebo-controlled, phase II trial of first-line platinum/docetaxel with or without erlotinib (E) in patients (pts) with recurrent and/or metastatic (R/M) head and neck squamous cell carcinomas (HNSCCs). Journal of Clinical Oncology. 35: 6017-6017. DOI: 10.1200/Jco.2017.35.15_Suppl.6017 |
0.327 |
|
| 2017 |
Singh R, Shen L, Tong P, Wang J, Johnson FM. Abstract 4095: c-Met activation mediates resistance to polo-like kinase 1 inhibitor-induced apoptosis in non-small cell lung cancer Cancer Research. 77: 4095-4095. DOI: 10.1158/1538-7445.Am2017-4095 |
0.466 |
|
| 2017 |
Zhang M, Ratnakar S, Peng S, Tuhina M, Li S, Tong P, Pickering C, Myers JN, Wang J, Johnson FM. Abstract 3816: Mutations of the lim protein ajuba mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell cycle inhibitors Cancer Research. 77: 3816-3816. DOI: 10.1158/1538-7445.Am2017-3816 |
0.403 |
|
| 2017 |
Sambandam V, Shen L, Tong P, Mazumdar T, Pickering C, Myers JN, Wang J, Frederick M, Johnson FM. Abstract 2992: Identification ofNOTCH1inactivating mutation as a therapeutic vulnerability to PI3K/mTOR pathway inhibition in head and neck squamous cell carcinoma (HNSCC) Cancer Research. 77: 2992-2992. DOI: 10.1158/1538-7445.Am2017-2992 |
0.484 |
|
| 2016 |
Quinlan-Davidson SR, Morrison WH, Myers JN, Gunn GB, William WN, Beadle BM, Skinner HD, Gillenwater AM, Frank SJ, Phan J, Johnson FM, Fuller CD, Zafereo ME, Rosenthal DI, Garden AS. Recurrent oral cavity cancer: Patterns of failure after salvage multimodality therapy. Head & Neck. PMID 28006086 DOI: 10.1002/Hed.24666 |
0.355 |
|
| 2016 |
Danilov AV, Hu S, Orr B, Godek K, Mustachio LM, Sekula D, Liu X, Kawakami M, Johnson FM, Compton DA, Freemantle SJ, Dmitrovsky E. Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin Dependent Kinases 1 and 2. Molecular Cancer Therapeutics. PMID 27550941 DOI: 10.1158/1535-7163.Mct-16-0127 |
0.492 |
|
| 2016 |
Murone M, Vaslin Chessex A, Attinger A, Ramachandra R, Shetty SJ, Daginakatte G, Sengupta S, Marappan S, Dhodheri S, Rigotti S, Bachhav Y, Brienza S, Traxler P, Lang M, Aguet M, ... ... Johnson FM, et al. Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases. Molecular Cancer Therapeutics. PMID 27439479 DOI: 10.1158/1535-7163.Mct-15-0974 |
0.445 |
|
| 2016 |
Garden AS, Fuller CD, Rosenthal DI, William WN, Gunn GB, Beadle BM, Johnson FM, Morrison WH, Phan J, Frank SJ, Kies MS, Sturgis EM. Reply to radiotherapy for human papillomavirus-positive oropharyngeal cancers in the National Cancer Data Base. Cancer. PMID 27420634 DOI: 10.1002/Cncr.30193 |
0.361 |
|
| 2016 |
Wang Y, Singh R, Wang L, Nilsson M, Goonatilake R, Tong P, Li L, Giri U, Villalobos P, Mino B, Rodriguez-Canales J, Wistuba I, Wang J, Heymach JV, Johnson FM. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations. Oncotarget. PMID 27384992 DOI: 10.18632/Oncotarget.10332 |
0.469 |
|
| 2016 |
Lee SC, Min HY, Jung HJ, Park KH, Hyun SY, Cho J, Woo JK, Kwon SJ, Lee HJ, Johnson FM, Lee HY. Essential role of insulin-like growth factor 2 in resistance to histone deacetylase inhibitors. Oncogene. PMID 27086926 DOI: 10.1038/Onc.2016.92 |
0.399 |
|
| 2016 |
Hong D, Infante J, Janku F, Jones S, Nguyen LM, Burris H, Naing A, Bauer TM, Piha-Paul S, Johnson FM, Kurzrock R, Golden L, Hynes S, Lin J, Lin AB, et al. Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27044938 DOI: 10.1200/Jco.2015.64.5788 |
0.402 |
|
| 2016 |
Garden AS, Fuller CD, Rosenthal DI, William WN, Gunn GB, Beadle BM, Johnson FM, Morrison WH, Phan J, Frank SJ, Kies MS, Sturgis EM. Radiation therapy (with or without neck surgery) for phenotypic human papillomavirus-associated oropharyngeal cancer. Cancer. PMID 27019396 DOI: 10.1002/Cncr.29965 |
0.358 |
|
| 2016 |
Zhang M, Peng S, Mazumdar T, Sambandam V, Shen L, Tong P, Li L, Byers L, Pickering C, Frederick M, Myers JN, Wang J, Johnson FM. Abstract 4757: Identification of biomarkers that predict response of head and neck squamous cell carcinoma to mitotic inhibitors Cancer Research. 76: 4757-4757. DOI: 10.1158/1538-7445.Am2016-4757 |
0.484 |
|
| 2016 |
Singh R, Wang Y, Wang L, Nilsson M, Goonatilake R, Tong P, Li L, Giri U, Wang J, Heymach JV, Johnson FM. Abstract 4665: The combination of polo-like kinase 1 inhibition and erlotinib overcomes T790M-mediated drug resistancein vitroandin vivoin non-small cell lung cancer Cancer Research. 76: 4665-4665. DOI: 10.1158/1538-7445.Am2016-4665 |
0.506 |
|
| 2016 |
Johnson FM, Sambandam V, Shen L, Zhang M, Saigal R, Tong P, Mazumdar T, Byers LA, Pickering C, Myers JN, Wang J, Frederick M. Abstract 393: NOTCH1 inactivating mutation mediates sensitivity to PI3K/mTOR inhibitors in head and neck squamous cell carcinoma Cancer Research. 76: 393-393. DOI: 10.1158/1538-7445.Am2016-393 |
0.48 |
|
| 2016 |
Kalu NN, Mazumdar T, Tong P, Shen L, Wang J, Byers LA, Johnson FM. Abstract 3793: Cell-based, high-throughput screen for small molecule inducers of cell death in HPV-associated head and neck cancers Cancer Research. 76: 3793-3793. DOI: 10.1158/1538-7445.Am2016-3793 |
0.372 |
|
| 2016 |
Cardnell R, Tong P, Giri U, Gudikote J, Banerjee U, Kalu N, Fan Y, Nilsson M, Johnson F, Tran H, Wang J, Heymach J, Byers L. A high-throughput drug screen identifies new therapeutic vulnerabilities in non-small cell lung cancers (NSCLC) with overexpression of the EMT-associated receptor tyrosine kinase AXL European Journal of Cancer. 69: S82. DOI: 10.1016/S0959-8049(16)32840-4 |
0.345 |
|
| 2016 |
Osman AA, Tanaka N, Silver NL, Kalu NN, Patel AA, Wang J, Tang L, Frederick MJ, Johnson FM, Fu S, Myers JN. A Regimen Combining the Wee1 Inhibitor AZD1775 With Histone Deacetylase Inhibitor Vorinostat is Highly Active Against Head and Neck Squamous Cell Carcinoma Harboring High-risk TP53 Mutations International Journal of Radiation Oncology Biology Physics. 94: 936. DOI: 10.1016/J.Ijrobp.2015.12.258 |
0.392 |
|
| 2015 |
Peng S, Sen B, Mazumdar T, Byers LA, Diao L, Wang J, Tong P, Giri U, Heymach JV, Kadara HN, Johnson FM. Dasatinib induces DNA damage and activates DNA repair pathways leading to senescence in non-small cell lung cancer cell lines with kinase-inactivating BRAF mutations. Oncotarget. PMID 26623721 DOI: 10.18632/Oncotarget.6376 |
0.454 |
|
| 2015 |
Ferrarotto R, Goonatilake R, Yoo SY, Tong P, Giri U, Peng S, Minna JD, Girard L, Wang Y, Wang L, Li L, Diao L, Peng DH, Gibbons DL, Glisson BS, ... ... Johnson FM, et al. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26597303 DOI: 10.1158/1078-0432.Ccr-14-2890 |
0.5 |
|
| 2015 |
Nien HH, Sturgis EM, Kies MS, El-Naggar AK, Morrison WH, Beadle BM, Johnson FM, Gunn GB, Fuller CD, Phan J, Gold KA, Frank SJ, Skinner H, Rosenthal DI, Garden AS. Comparison of systemic therapies used concurrently with radiation for the treatment of human papillomavirus-associated oropharyngeal cancer. Head & Neck. PMID 26595157 DOI: 10.1002/Hed.24278 |
0.343 |
|
| 2015 |
Osman AA, Tanaka N, Patel AA, Wang J, Frederick MJ, Kalu NN, Zhao M, Fitzgerald AL, Xie TX, Silver NL, Caulin C, Zhou G, Skinner HD, Johnson FM, Myers JN. Wee-1 kinase inhibition sensitizes high risk HPV+ HNSCC to apoptosis accompanied by downregulation of MCl-1 and XIAP antiapoptotic proteins. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26124202 DOI: 10.1158/1078-0432.Ccr-15-0279 |
0.423 |
|
| 2015 |
Mazumdar T, Sen B, Wang Y, Peng S, Nicholas C, Glisson BS, Myers JN, Johnson FM. Drug-induced RAF dimerization is independent of RAS mutation status and does not lead to universal MEK dependence for cell survival in head and neck cancers. Anti-Cancer Drugs. 26: 835-42. PMID 26053277 DOI: 10.1097/Cad.0000000000000251 |
0.448 |
|
| 2015 |
Hao C, Wang L, Peng S, Cao M, Li H, Hu J, Huang X, Liu W, Zhang H, Wu S, Pataer A, Heymach JV, Eterovic AK, Zhang Q, Shaw KR, ... ... Johnson FM, et al. Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. Cancer Letters. 357: 179-85. PMID 25444907 DOI: 10.1016/J.Canlet.2014.11.024 |
0.391 |
|
| 2015 |
Jones RL, Kim ES, Nava-Parada P, Alam S, Johnson FM, Stephens AW, Simantov R, Poondru S, Gedrich R, Lippman SM, Kaye SB, Carden CP. Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 693-700. PMID 25208878 DOI: 10.1158/1078-0432.Ccr-14-0265 |
0.327 |
|
| 2015 |
Recondo G, Busaidy N, Erasmus J, Williams MD, Johnson FM. Spindle epithelial tumor with thymus-like differentiation: A case report and comprehensive review of the literature and treatment options. Head & Neck. 37: 746-54. PMID 24677409 DOI: 10.1002/Hed.23634 |
0.332 |
|
| 2015 |
Massarelli E, Haddad RI, Lee JJ, Lin HY, Garden AS, Blumenschein GR, William WN, Tishler RB, Glisson BS, Gold KA, Johnson FM, Rabinowits G, Ginsberg LE, Williams MD, Myers J, et al. Weekly paclitaxel, carboplatin, cetuximab (PCC), and cetuximab, docetaxel, cisplatin, and fluorouracil (C-TPF), followed by risk-based local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma (LAHNSCC). Journal of Clinical Oncology. 33: 6001-6001. DOI: 10.1200/Jco.2015.33.15_Suppl.6001 |
0.315 |
|
| 2015 |
Kato S, Jardim DLF, Johnson FM, Subbiah V, Piha-Paul SA, Tsimberidou AM, Falchook GS, Karp DD, Wheler JJ, Zinner R, Janku F, Fu S, Dandu L, Browne E, Meric-Bernstam F, et al. Phase I study of combination of crizotinib (C) and dasatinib (D) in patients (pts) with advanced cancer. Journal of Clinical Oncology. 33: 2597-2597. DOI: 10.1200/Jco.2015.33.15_Suppl.2597 |
0.319 |
|
| 2015 |
Johnson F, Sen B, Mazumdar T, Peng S, Kadara H, Diao L, Byers L. Abstract IA10: Kinase-impaired BRAF mutations as predictors of resistance and sensitivity Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Pms14-Ia10 |
0.501 |
|
| 2015 |
Sambandam V, Shen L, Zhang M, Saigal R, Byers LA, Pickering C, Myers JN, Wang J, Johnson FM. Abstract 417: Integrative drug sensitivity analysis of PI3K /mTOR pathway inhibitors in Head and Neck Squamous Cell Carcinoma (HNSCC) Cancer Research. 75: 417-417. DOI: 10.1158/1538-7445.Am2015-417 |
0.424 |
|
| 2015 |
Zhang M, Mazumdar T, Peng S, Tong P, Sambandam V, Byers LA, Myers JN, Wang J, Johnson FM. Abstract 2427: The difference of drug sensitivity between HPV-positive and HPV-negative head and neck squamous cell carcinoma cell lines Cancer Research. 75: 2427-2427. DOI: 10.1158/1538-7445.Am2015-2427 |
0.376 |
|
| 2015 |
Kalu NN, Mazumdar T, Diao L, Ng PKS, Wang J, Myers J, Johnson FM, Byers LA. Abstract 1826: Characterization of HPV-positive head and neck cancer cell lines as preclinical models for targeted therapy Cancer Research. 75: 1826-1826. DOI: 10.1158/1538-7445.Am2015-1826 |
0.383 |
|
| 2015 |
Garden AS, Fuller CD, Dahlstrom KR, Morrison WH, William WN, Beadle BM, Gunn GB, Johnson FM, Phan J, Frank SJ, Rosenthal DI, Sturgis EM. Applying Nasopharyngeal Nodal Staging to HPV Associated Oropharyngeal Cancer International Journal of Radiation Oncology Biology Physics. 93. DOI: 10.1016/J.Ijrobp.2015.07.1391 |
0.323 |
|
| 2014 |
Mazumdar T, Byers LA, Ng PK, Mills GB, Peng S, Diao L, Fan YH, Stemke-Hale K, Heymach JV, Myers JN, Glisson BS, Johnson FM. A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma. Molecular Cancer Therapeutics. 13: 2738-50. PMID 25193510 DOI: 10.1158/1535-7163.Mct-13-1090 |
0.465 |
|
| 2014 |
Gold KA, Lee JJ, Harun N, Tang X, Price J, Kawedia JD, Tran HT, Erasmus JJ, Blumenschein GR, William WN, Wistuba II, Johnson FM. A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer. The Oncologist. 19: 1040-1. PMID 25170013 DOI: 10.1634/Theoncologist.2014-0228 |
0.477 |
|
| 2014 |
Massarelli E, Haddad RI, Lee JJ, Garden AS, Blumenschein GR, William WN, Tishler RB, Glisson BS, Gold KA, Johnson FM, Ginsberg LE, Williams MD, Myers J, Kies MS, Papadimitrakopoulou V. Randomized phase II trial of weekly paclitaxel, carboplatin, cetuximab (PCC) versus cetuximab, docetaxel, cisplatin, and fluorouracil (C-TPF) in previously untreated patients with locally advanced head and neck squamous cell carcinoma. Journal of Clinical Oncology. 32: TPS6102-TPS6102. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps6102 |
0.393 |
|
| 2014 |
Bauman JE, Duvvuri U, Gooding WE, Gross ND, Song J, Yarbrough WG, Johnson FM, Wang L, Jimeno A, Sen M, Kass JI, Johnson JT, Ferris RL, Kim S, Rath TJ, et al. Erlotinib, dasatinib, erlotinib-dasatinib versus placebo: A randomized, double-blind window study in operable head and neck squamous cell carcinoma (HNSCC). Journal of Clinical Oncology. 32: 6033-6033. DOI: 10.1200/Jco.2014.32.15_Suppl.6033 |
0.412 |
|
| 2014 |
Byers LA, Diao L, Ng PKS, Heymach C, Fan YH, El-Naggar AK, Wang J, Mills GB, Johnson FM. Proteomic profiling of HPV-positive head and neck cancer to identify new candidates for targeted therapy. Journal of Clinical Oncology. 32: 6030-6030. DOI: 10.1200/Jco.2014.32.15_Suppl.6030 |
0.331 |
|
| 2014 |
Mazumdar T, Byers LA, Ng P, Mills GB, Peng S, Diao L, Fan Y, Stemke-Hale K, Heymach JV, Myers JN, Glisson BS, Johnson FM. Abstract 903: Evaluation of predictive biomarkers and resistance mechanisms of PI3K pathway inhibition in head and neck squamous cell carcinoma Cancer Research. 74: 903-903. DOI: 10.1158/1538-7445.Am2014-903 |
0.491 |
|
| 2014 |
Sen B, Peng S, Mazumdar T, Byers LA, Kadara H, Johnson FM. Abstract 3707: The multitargeted kinase inhibitor dasatinib induces DNA damage, Hippo pathway engagement and senescence in lung cancer cell lines that possess kinase-inactivating BRAF mutations Cancer Research. 74: 3707-3707. DOI: 10.1158/1538-7445.Am2014-3707 |
0.524 |
|
| 2014 |
Quinlan-Davidson S, Morrison W, Myers J, Gunn G, Johnson F, Beadle B, Gillenwater A, Phan J, Frank S, William W, Fuller C, Gold K, Rosenthal D, Garden A. Postoperative IMRT for Patients With Oral Cavity Carcinoma International Journal of Radiation Oncology*Biology*Physics. 90: S508. DOI: 10.1016/J.Ijrobp.2014.05.1559 |
0.31 |
|
| 2013 |
Shin DH, Lee HJ, Min HY, Choi SP, Lee MS, Lee JW, Johnson FM, Mehta K, Lippman SM, Glisson BS, Lee HY. Combating resistance to anti-IGFR antibody by targeting the integrin β3-Src pathway. Journal of the National Cancer Institute. 105: 1558-70. PMID 24092920 DOI: 10.1093/Jnci/Djt263 |
0.359 |
|
| 2013 |
Peng S, Creighton CJ, Zhang Y, Sen B, Mazumdar T, Myers JN, Lai SY, Woolfson A, Lorenzi MV, Bell D, Williams MD, Johnson FM. Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and histologic characteristics of human cancers. Journal of Translational Medicine. 11: 198. PMID 23981300 DOI: 10.1186/1479-5876-11-198 |
0.389 |
|
| 2013 |
Massarelli E, Johnson FM, Erickson HS, Wistuba II, Papadimitrakopoulou V. Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance. Lung Cancer (Amsterdam, Netherlands). 80: 235-41. PMID 23485129 DOI: 10.1016/J.Lungcan.2013.01.018 |
0.423 |
|
| 2013 |
Guo C, Shao R, Correa AM, Behrens C, Johnson FM, Raso MG, Prudkin L, Solis LM, Nunez MI, Fang B, Roth JA, Wistuba II, Swisher SG, Lin T, Pataer A. Prognostic significance of combinations of RNA-dependent protein kinase and EphA2 biomarkers for NSCLC. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 8: 301-8. PMID 23370317 DOI: 10.1097/Jto.0B013E318282Def7 |
0.433 |
|
| 2013 |
Sandulache VC, Ow TJ, Daram SP, Hamilton J, Skinner H, Bell D, Rosenthal DI, Beadle BM, Ang KK, Kies MS, Johnson FM, El-Naggar AK, Myers JN. Residual nodal disease in patients with advanced-stage oropharyngeal squamous cell carcinoma treated with definitive radiation therapy and posttreatment neck dissection: Association with locoregional recurrence, distant metastasis, and decreased survival. Head & Neck. 35: 1454-60. PMID 23018868 DOI: 10.1002/Hed.23173 |
0.362 |
|
| 2013 |
Johnson FM, Tang X, Tran HT, Mc Intyre C, Price J, Lee JJ, Harun N, Wistuba II, Gold KA. A phase I/II study combining dasatinib (D) and erlotinib (E) in non-small cell lung cancer. Journal of Clinical Oncology. 31: 8102-8102. DOI: 10.1200/Jco.2013.31.15_Suppl.8102 |
0.43 |
|
| 2013 |
Tran HT, Melnikova VO, Tsao AS, Fossella FV, Johnson FM, Papadimitrakopoulou V, Garza M, Neal C, Hasegawa D, Kruempel A, Wu G, Richardson K, Lewis ME, Legendre BJ, Anderes KL, et al. Characterization and identification of specific EGFR mutations in circulating tumor cells (CTCs) isolated from non-small cell lung cancer patients using antibody independent method, ApoStream. Journal of Clinical Oncology. 31: 11044-11044. DOI: 10.1200/Jco.2013.31.15_Suppl.11044 |
0.396 |
|
| 2013 |
Lee J, Kang J, Boo H, Myers JN, Johnson FM, Glisson BS, Oh S, Lee H. Abstract 5645: Angiogenic activity leads failure of antitumor activity of cixutumumab, an anti-Insulin like growth factor receptor monoclonal antibody. Cancer Research. 73: 5645-5645. DOI: 10.1158/1538-7445.Am2013-5645 |
0.464 |
|
| 2013 |
Nicholas C, Nunez MI, Harun N, Lee JJ, Myers J, Wistuba II, Sen B, El-Naggar AK, Lai SY, Johnson FM, William WN. Abstract 5578: SOCS2 (suppressor of cytokine signaling protein 2) is a prognostic indicator of progression-free survival in head and neck squamous cell carcinoma (HNSCC) patients. Cancer Research. 73: 5578-5578. DOI: 10.1158/1538-7445.Am2013-5578 |
0.446 |
|
| 2013 |
Sen B, Mazumdar T, Peng S, Hale KS, Glisson BS, Johnson FM. Abstract 4095: Paradoxical activation of the RAF-MEK-ERK pathway in response to nilotinib induces synthetic lethality with MEK inhibition in head and neck cancer cells. Cancer Research. 73: 4095-4095. DOI: 10.1158/1538-7445.Am2013-4095 |
0.466 |
|
| 2013 |
Peng S, Creighton C, Zhang Y, Sen B, Mazumdar T, Myers J, Bell D, El-Naggar A, Williams M, Johnson F. Abstract 333: Molecular and histologic characterization a patient-derived heterotransplant mouse model of head and neck squamous carcinoma. Cancer Research. 73: 333-333. DOI: 10.1158/1538-7445.Am2013-333 |
0.406 |
|
| 2013 |
Mazumdar T, Byers LA, Peng S, Diao L, Hale KS, Glisson BS, Johnson FM. Abstract 2388: Genetic determinants of sensitivity and resistance to PI3K inhibitors in head and neck cancers for efficient targeted therapy. Cancer Research. 73: 2388-2388. DOI: 10.1158/1538-7445.Am2013-2388 |
0.491 |
|
| 2013 |
Tran HT, Melnikova V, Tsao AS, Fossella FV, Johnson FM, Papadimitrakoupoulou V, Richardson K, Lewis ME, Legendre B, Anderes KL, Davis DW, Heymach JV. Abstract C29: Characterization and identification of specific EGFR mutations in circulating tumor cells (CTCs) isolated from non-small cell lung cancer patients using an antibody independent method, ApoStream™: An update report. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C29 |
0.457 |
|
| 2013 |
Ferrarotto R, Suryavanshi M, Yoo SY, Wang J, Byers L, Glisson BS, Heymach J, Johnson FM. Abstract A182: Identifying biomarkers of sensitivity to polo-like kinase inhibitors (Plki) in non small cell lung cancer (NSCLC). Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-A182 |
0.464 |
|
| 2012 |
Raju U, Riesterer O, Wang ZQ, Molkentine DP, Molkentine JM, Johnson FM, Glisson B, Milas L, Ang KK. Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 105: 241-9. PMID 23010482 DOI: 10.1016/J.Radonc.2012.08.010 |
0.462 |
|
| 2012 |
Saintigny P, Peng S, Zhang L, Sen B, Wistuba II, Lippman SM, Girard L, Minna JD, Heymach JV, Johnson FM. Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion. Molecular Cancer Therapeutics. 11: 2021-32. PMID 22807579 DOI: 10.1158/1535-7163.Mct-12-0030 |
0.442 |
|
| 2012 |
Sen B, Peng S, Tang X, Erickson HS, Galindo H, Mazumdar T, Stewart DJ, Wistuba I, Johnson FM. Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib. Science Translational Medicine. 4: 136ra70. PMID 22649091 DOI: 10.1126/Scitranslmed.3003513 |
0.487 |
|
| 2012 |
Sen B, Peng S, Woods DM, Wistuba I, Bell D, El-Naggar AK, Lai SY, Johnson FM. STAT5A-mediated SOCS2 expression regulates Jak2 and STAT3 activity following c-Src inhibition in head and neck squamous carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 127-39. PMID 22090359 DOI: 10.1158/1078-0432.Ccr-11-1889 |
0.4 |
|
| 2012 |
Sen B, Peng S, Tang X, Erickson H, Galindo H, Mazumdar T, Stewart DJ, Wistuba I, Johnson FM. Abstract 3667: Inactivating BRAF mutations confer dasatinib sensitivity in lung cancer Cancer Research. 72: 3667-3667. DOI: 10.1158/1538-7445.Am2012-3667 |
0.473 |
|
| 2012 |
Peng S, Sen B, Mazumdar T, Myers J, Bell D, Williams M, El-Naggar A, Johnson FM. Abstract 2361: Establishing a patient-derived heterotransplant mouse model of head and neck squamous carcinoma (HNSCC) Cancer Research. 72: 2361-2361. DOI: 10.1158/1538-7445.Am2012-2361 |
0.421 |
|
| 2012 |
Brooks HD, Glisson BS, Bekele N, Johnson FM, Ginsberg LE, El-Naggar AK, Culotta KS, Takebe N, Wright J, Tran HT, Papadimitrakopoulou VA. Erratum: Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma (Cancer (2011) 117 (2112-2119)) Cancer. 118. DOI: 10.1002/Cncr.26531 |
0.4 |
|
| 2011 |
Sen B, Johnson FM. Regulation of SRC family kinases in human cancers. Journal of Signal Transduction. 2011: 865819. PMID 21776389 DOI: 10.1155/2011/865819 |
0.472 |
|
| 2011 |
Sen B, Peng S, Saigal B, Williams MD, Johnson FM. Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 514-24. PMID 21106725 DOI: 10.1158/1078-0432.Ccr-10-1617 |
0.372 |
|
| 2011 |
Sen B, Peng S, Saigal B, Williams M, Johnson FM. Abstract 1046: Differential interactions between c-Src and c-Met mediate resistance to c-Src inhibitors Cancer Research. 71: 1046-1046. DOI: 10.1158/1538-7445.Am2011-1046 |
0.446 |
|
| 2010 |
Johnson FM, Bekele BN, Feng L, Wistuba I, Tang XM, Tran HT, Erasmus JJ, Hwang LL, Takebe N, Blumenschein GR, Lippman SM, Stewart DJ. Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 4609-15. PMID 20855820 DOI: 10.1200/Jco.2010.30.5474 |
0.491 |
|
| 2010 |
Rothschild SI, Gautschi O, Haura EB, Johnson FM. Src inhibitors in lung cancer: current status and future directions. Clinical Lung Cancer. 11: 238-42. PMID 20630825 DOI: 10.3816/Clc.2010.N.030 |
0.494 |
|
| 2010 |
Taoudi Benchekroun M, Saintigny P, Thomas SM, El-Naggar AK, Papadimitrakopoulou V, Ren H, Lang W, Fan YH, Huang J, Feng L, Lee JJ, Kim ES, Hong WK, Johnson FM, Grandis JR, et al. Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prevention Research (Philadelphia, Pa.). 3: 800-9. PMID 20570883 DOI: 10.1158/1940-6207.Capr-09-0163 |
0.387 |
|
| 2010 |
Haura EB, Camidge DR, Reckamp K, Chiappori A, Johnson F, Herbst R, Wong K, Carbone D. Molecular origins of lung cancer: prospects for personalized prevention and therapy. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 5: S207-13. PMID 20502275 DOI: 10.1097/Jto.0B013E3181E2F682 |
0.418 |
|
| 2010 |
Lai SY, Johnson FM. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 13: 67-78. PMID 20471303 DOI: 10.1016/J.Drup.2010.04.001 |
0.489 |
|
| 2010 |
William WN, Uyeki J, Johnson FM, Feng L, Peeples BO, Fossella FV, Karp DD, Blumenschein GR, Stewart DJ, Glisson BS. Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma. Cancer. 116: 2409-15. PMID 20225329 DOI: 10.1002/Cncr.25076 |
0.389 |
|
| 2010 |
Xu L, Nilsson MB, Saintigny P, Cascone T, Herynk MH, Du Z, Nikolinakos PG, Yang Y, Prudkin L, Liu D, Lee JJ, Johnson FM, Wong KK, Girard L, Gazdar AF, et al. Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells. Oncogene. 29: 2616-27. PMID 20154724 DOI: 10.1038/Onc.2010.16 |
0.46 |
|
| 2010 |
Johnson FM, Agrawal S, Burris H, Rosen L, Dhillon N, Hong D, Blackwood-Chirchir A, Luo FR, Sy O, Kaul S, Chiappori AA. Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer. 116: 1582-91. PMID 20108303 DOI: 10.1002/Cncr.24927 |
0.351 |
|
| 2010 |
Carden CP, Kim ES, Jones RL, Alam SM, Johnson FM, Stephens AW, Poondru S, Gedrich R, Lippman SM, Kaye SB. Phase I study of intermittent dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF- 1R) and insulin receptor (IR) in patients with advanced solid tumors. Journal of Clinical Oncology. 28: 2530-2530. DOI: 10.1200/Jco.2010.28.15_Suppl.2530 |
0.34 |
|
| 2010 |
Sen B, Peng S, Johnson FM. Abstract 4005: JAK/STAT activation following Src inhibition is mediated by the loss of SOCS2 expression Cancer Research. 70: 4005-4005. DOI: 10.1158/1538-7445.Am10-4005 |
0.403 |
|
| 2009 |
Johnson FM, Tang X, Tran H, Saigal B, Erasmus J, Kurie J, Hwang L, Oh Y, Lippman S, Stewart DJ. Phase II study of dasatinib in non-small cell lung cancer (NSCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e19015. PMID 27962619 DOI: 10.1200/Jco.2009.27.15_Suppl.E19015 |
0.507 |
|
| 2009 |
Brooks HD, Glisson B, Lu C, Sabichi A, Johnson F, Ginsberg L, Bekele B, Papadimitrakopoulou V. Phase II study of dasatinib in the treatment of head and neck squamous cell carcinoma (HNSCC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 6022. PMID 27962430 DOI: 10.1200/Jco.2009.27.15_Suppl.6022 |
0.382 |
|
| 2009 |
Zinner R, Herbst RS, Fossella FV, Johnson FM, Karp DD, Kies MS, Heymach JV, Price JS, Lippman SM, Erasmus J. Results from short-term CT assessments in patients (pts) with advanced poor performance status non-small cell lung cancer (NSCLC) receiving pemetrexed in a phase II trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e19069. PMID 27962140 DOI: 10.1200/Jco.2009.27.15_Suppl.E19069 |
0.369 |
|
| 2009 |
Brannan JM, Sen B, Saigal B, Prudkin L, Behrens C, Solis L, Dong W, Bekele BN, Wistuba I, Johnson FM. EphA2 in the early pathogenesis and progression of non-small cell lung cancer. Cancer Prevention Research (Philadelphia, Pa.). 2: 1039-49. PMID 19934338 DOI: 10.1158/1940-6207.Capr-09-0212 |
0.764 |
|
| 2009 |
Byers LA, Sen B, Saigal B, Diao L, Wang J, Nanjundan M, Cascone T, Mills GB, Heymach JV, Johnson FM. Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 6852-61. PMID 19861436 DOI: 10.1158/1078-0432.Ccr-09-0767 |
0.448 |
|
| 2009 |
Johnson FM, Glisson BS. Chemotherapy: Irinotecan or etoposide as front-line therapy for SCLC? Nature Reviews. Clinical Oncology. 6: 562-3. PMID 19786998 DOI: 10.1038/Nrclinonc.2009.141 |
0.429 |
|
| 2009 |
Brannan JM, Dong W, Prudkin L, Behrens C, Lotan R, Bekele BN, Wistuba I, Johnson FM. Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4423-30. PMID 19531623 DOI: 10.1158/1078-0432.Ccr-09-0473 |
0.753 |
|
| 2009 |
Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, Blakely LJ, Eisenberg PD, Langer CJ, Blumenschein G, Johnson FM, Green S, Gualberto A. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2516-22. PMID 19380445 DOI: 10.1200/Jco.2008.19.9331 |
0.432 |
|
| 2009 |
Sen B, Saigal B, Parikh N, Gallick G, Johnson FM. Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding. Cancer Research. 69: 1958-65. PMID 19223541 DOI: 10.1158/0008-5472.Can-08-2944 |
0.442 |
|
| 2008 |
Braiteh F, Kurzrock R, Johnson FM. Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 3460-2. PMID 18612164 DOI: 10.1200/Jco.2008.16.9391 |
0.408 |
|
| 2008 |
Saigal B, Glisson BS, Johnson FM. Dose-dependent and sequence-dependent cytotoxicity of erlotinib and docetaxel in head and neck squamous cell carcinoma. Anti-Cancer Drugs. 19: 465-75. PMID 18418213 DOI: 10.1097/Cad.0B013E3282Fc46C4 |
0.421 |
|
| 2008 |
Yang Y, Wislez M, Fujimoto N, Prudkin L, Izzo JG, Uno F, Ji L, Hanna AE, Langley RR, Liu D, Johnson FM, Wistuba I, Kurie JM. A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras. Molecular Cancer Therapeutics. 7: 952-60. PMID 18413809 DOI: 10.1158/1535-7163.Mct-07-2045 |
0.434 |
|
| 2008 |
Mandal M, Myers JN, Lippman SM, Johnson FM, Williams MD, Rayala S, Ohshiro K, Rosenthal DI, Weber RS, Gallick GE, El-Naggar AK. Epithelial to mesenchymal transition in head and neck squamous carcinoma: association of Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features. Cancer. 112: 2088-100. PMID 18327819 DOI: 10.1002/Cncr.23410 |
0.413 |
|
| 2007 |
Johnson FM, Gallick GE. SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy. Anti-Cancer Agents in Medicinal Chemistry. 7: 651-9. PMID 18045060 DOI: 10.2174/187152007784111278 |
0.483 |
|
| 2007 |
Johnson FM, Saigal B, Tran H, Donato NJ. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 4233-44. PMID 17634553 DOI: 10.1158/1078-0432.Ccr-06-2981 |
0.434 |
|
| 2007 |
Tsao AS, He D, Saigal B, Liu S, Lee JJ, Bakkannagari S, Ordonez NG, Hong WK, Wistuba I, Johnson FM. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Molecular Cancer Therapeutics. 6: 1962-72. PMID 17620427 DOI: 10.1158/1535-7163.Mct-07-0052 |
0.429 |
|
| 2007 |
Zhang J, Kalyankrishna S, Wislez M, Thilaganathan N, Saigal B, Wei W, Ma L, Wistuba II, Johnson FM, Kurie JM. SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. The American Journal of Pathology. 170: 366-76. PMID 17200208 DOI: 10.2353/Ajpath.2007.060706 |
0.495 |
|
| 2007 |
Tsao AS, He DD, Saigal B, Liu S, Lee J, Bakkannagari S, Ordonez N, Hong W, Wistuba I, Johnson F. Activated Src kinase is expressed in malignant pleural mesothelioma tumors; dasatinib inhibition leads to cytotoxicity, cell cycle inhibition, and prevention of invasion and migration Journal of Clinical Oncology. 25: 7713-7713. DOI: 10.1200/Jco.2007.25.18_Suppl.7713 |
0.421 |
|
| 2007 |
Glisson BS, Saigal B, Xu Y, Johnson FM. Sequence-dependent cytoxicity of docetaxel and erlotinib in head and neck squamous cell carcinoma (HNSCC) Journal of Clinical Oncology. 25: 6084-6084. DOI: 10.1200/Jco.2007.25.18_Suppl.6084 |
0.498 |
|
| 2007 |
El-Naggar AK, Lippman SM, Johnson FM, Mandal M, Myers JN, Williams MD, Rosenthal DI, Weber RS, Gallick G. Correlation of Src activation with epithelial-mesenchymal transformation and aggressive features of head and neck squamous carcinoma Journal of Clinical Oncology. 25: 6026-6026. DOI: 10.1200/Jco.2007.25.18_Suppl.6026 |
0.318 |
|
| 2007 |
Uyeki J, Johnson FM, Feng L, Peeples BO, Blumenschein GJ, Fossella FV, Karp DD, Pisters KM, Stewart DJ, Glisson BS. Phase II trial of irinotecan plus cisplatin (IP) and etoposide plus cisplatin (EP) given weekly on alternating weeks with granulocyte colony-stimulating factor support in the treatment of extensive-stage small cell lung cancer Journal of Clinical Oncology. 25: 18119-18119. DOI: 10.1200/Jco.2007.25.18_Suppl.18119 |
0.414 |
|
| 2007 |
Johnson FM, Chiappori A, Burris H, Rosen L, McCann B, Luo FR, Mayfield S, Palme H, Platero J, Blackwood-Chirchir A. A phase I study (CA180021-Segment 2) of dasatinib in patients (pts) with advanced solid tumors Journal of Clinical Oncology. 25: 14042-14042. DOI: 10.1200/Jco.2007.25.18_Suppl.14042 |
0.371 |
|
| 2007 |
Zinner RG, Fossella FV, Kies M, Herbst RS, Lu C, Johnson F, Price J, Cleeland C, Wang S. P3-164: A phase II trial of pemetrexed(p) in patients (pts) with performance status (PS) 2 and 3 as 1st– and 2nd– line treatment for advanced non–small–cell lung cancer (NSCLC) Journal of Thoracic Oncology. 2: S749. DOI: 10.1097/01.Jto.0000284139.01895.99 |
0.39 |
|
| 2006 |
Johnson FM, Krug LM, Tran HT, Shoaf S, Prieto VG, Tamboli P, Peeples B, Patel J, Glisson BS. Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma. Cancer. 106: 366-74. PMID 16342249 DOI: 10.1002/Cncr.21640 |
0.476 |
|
| 2005 |
Johnson FM, Saigal B, Talpaz M, Donato NJ. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 6924-32. PMID 16203784 DOI: 10.1158/1078-0432.Ccr-05-0757 |
0.511 |
|
| 2005 |
Johnson FM, Garden AS, Palmer JL, Shin DM, Morrison W, Papadimitrakopoulou V, Khuri F, Clayman G, Goepfert H, Ang KK, Hong WK, Glisson BS. A phase I/II study of neoadjuvant chemotherapy followed by radiation with boost chemotherapy for advanced T-stage nasopharyngeal carcinoma. International Journal of Radiation Oncology, Biology, Physics. 63: 717-24. PMID 16199307 DOI: 10.1016/J.Ijrobp.2005.03.001 |
0.331 |
|
| 2005 |
Johnson FM, Saigal B, Donato NJ. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells. Journal of Cellular Physiology. 205: 218-27. PMID 15887238 DOI: 10.1002/Jcp.20383 |
0.436 |
|
| 2004 |
Johnson FM, Tran HT, Prieto VG, Tamboli P, Peeples BO, Glisson BS. Phase I trial of imatinib mesylate (IM), cisplatin (P), and irinotecan (I) in small cell lung cancer (SCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 7257. PMID 28013908 DOI: 10.1200/jco.2004.22.14_suppl.7257 |
0.38 |
|
| 2004 |
Johnson FM, Yang P, Newman RA, Donato NJ. Cyclooxygenase-2 induction and prostaglandin E2 accumulation in squamous cell carcinoma as a consequence of epidermal growth factor receptor activation by imatinib mesylate. Journal of Experimental Therapeutics & Oncology. 4: 317-25. PMID 15844661 |
0.352 |
|
| 2004 |
Johnson FM, Garden A, Palmer JL, Kies M, Clayman G, Brumfield B, Khuri FR, Morrison W, Papadimitrakopoulou V, Diaz EM, Glisson BS. A Phase II study of docetaxel and carboplatin as neoadjuvant therapy for nasopharyngeal carcinoma with early T status and advanced N status. Cancer. 100: 991-8. PMID 14983495 DOI: 10.1002/Cncr.20079 |
0.383 |
|
| 2004 |
Johnson FM, Tran HT, Prieto VG, Tamboli P, Peeples BO, Glisson BS. Phase I trial of imatinib mesylate (IM), cisplatin (P), and irinotecan (I) in small cell lung cancer (SCLC) Journal of Clinical Oncology. 22: 7257-7257. DOI: 10.1200/Jco.2004.22.90140.7257 |
0.437 |
|
| 2003 |
Johnson FM, Kurie JM, Peeples BO, Lee JJ, Feng L, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer. Clinical Lung Cancer. 5: 40-5. PMID 14596703 DOI: 10.3816/Clc.2003.N.020 |
0.331 |
|
| 2003 |
Johnson FM, Kurie JM, Peeples BO, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer. Oncology (Williston Park, N.Y.). 17: 17-21. PMID 12886869 |
0.377 |
|
| Show low-probability matches. |